Soy Isoflavone Nutritional Supplements
Preclinical
Soy Isoflavone Nutritional Supplements is one of 10 therapeutic programs targeting Wheezing. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
11 competitors in Wheezing
#DrugCompanyPhaseTrials
1Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Spiriva
Boehringer IngelheimApproved
Flovent
PParatek Pharmaceuticals Inc
Approved
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Broncho-Vaxom
OOM Pharma SA
Phase 3
Prednisolone Sodium Phosphate
UUniversity of Oulu
Phase 3
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Resveratrol
NNational Cancer Institute (NCI)
Preclinical
Inhaled Albuterol
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Soy Isoflavone Nutritional Supplements
AAnn & Robert H Lurie Children's Hospital of Chicago
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Wheezing1 trial
Genes, Soy Isoflavones, and Virus - Preventing Airway Remodeling, Asthma, and Wheezing Study
Not yet recruiting·AAnn & Robert H Lurie Children's Hospital of Chicago·Preclinical·NCT07828405·60 enrolled
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]